Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye diseases
Biotech
Regeneron ends eye disease trial following safety review
The Titan study tested REGN7041, an anti-CD3 monoclonal antibody, in patients with inflammation of the uvea, the eye’s middle layer.
Darren Incorvaia
Aug 17, 2026 2:30pm
Novo Holdings-backed Claris Bio emerges with $118M
Jul 28, 2026 8:00am
Ocugen’s CEO wants to bring gene therapy to the masses
Apr 16, 2026 9:00am
Scientists turn pig semen extract into cancer-killing eye drops
Mar 27, 2026 2:39pm
UK biotech eyes $1B deal to deliver eye gene therapy at doctor
Jan 6, 2026 6:25am
Lilly bags eye-catching gene therapy in $475M deal
Nov 10, 2025 7:00am
